Aflibercept rescues vision after laser for diabetic macular edema

December 29, 2016

(HealthDay)—For eyes experiencing substantial visual loss after macular laser photocoagulation treatment for diabetic macular edema (DME), intravitreal aflibercept improves visual and anatomic outcomes, according to a study published online Dec. 22 in JAMA Ophthalmology.

Charles C. Wykoff, M.D., Ph.D., from Retina Consultants of Houston, and colleagues examined outcomes in 63 of 154 eyes in Study of Intravitreal Aflibercept Injection in Patients With Diabetic Macular Edema (VISTA) and 46 of 133 eyes in Intravitreal Aflibercept Injection in Vision Impairment Due to DME (VIVID). The eyes were initially randomized to laser control and received intravitreal aflibercept treatment.

The researchers found that from baseline to week 100, the mean visual gain was 2.2 and 3.8 letters in VISTA and VIVID, respectively. These eyes had a mean loss of 11.0 and 10.0 letters, respectively, from baseline, at the time of initiation of intravitreal aflibercept injection; from the initiation of treatment through week 100, the eyes gained a mean of 17.4 and 13.6 letters, respectively. At the time of intravitreal aflibercept injection initiation, there was a minimal mean change in central subfield thickness from baseline (increase of 3.9 µm in VISTA and decrease of 3.0 µm in VIVID); subsequently, there were further mean reductions of 285.6 and 313.4 µm in VISTA and VIVID, respectively, through week 100.

"Intravitreal aflibercept injection improves visual and anatomic outcomes in eyes experiencing substantial vision loss after macular laser photocoagulation for DME," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Regeneron (the manufacturer of aflibercept) and Bayer HealthCare, both of which funded the VISTA and VIVID trials.

Explore further: High-priced drugs used to treat diabetic macular edema not cost-effective

More information: Full Text

Related Stories

Ranibizumab no better than saline for vitreous hemorrhage

February 1, 2013

(HealthDay)—For patients with vitreous hemorrhage from proliferative diabetic retinopathy (PDR), the probability of vitrectomy within 16 weeks after intravitreal injections of ranibizumab or saline is lower than expected, ...

Vitreolytic ocriplasmin resolves vitreomacular traction

August 16, 2012

(HealthDay) -- Intravitreal injection of the vitreolytic agent ocriplasmin resolves vitreomacular traction and closes macular holes significantly better than placebo, but with a higher incidence of adverse events, according ...

Aflibercept in macular oedema: Added benefit not proven

January 7, 2014

For the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG) dealt with the drug aflibercept. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal ...

Pharmaceutical payments linked to anti-VEGF injection use

June 30, 2016

(HealthDay)—There is a positive association between reported pharmaceutical payments and use of aflibercept and ranibizumab injections among ophthalmologists who prescribe anti-vascular endothelial growth factor (VEGF) ...

Recommended for you

Surgery can restore vision in patients with brain injuries

December 12, 2016

Surgery can restore vision in patients who have suffered hemorrhaging in the eye after a traumatic brain injury, even if the operation doesn't occur until several months after the injury, according to a small study from vision ...

An eye on young specialists' success

December 5, 2016

Graduates from several medical and surgical specialties are having difficulty securing practice opportunities, especially in specialties dependent upon limited resources, according to new research from Queen's ophthalmologist ...

'Halo' effect common after lasik eye surgery

December 3, 2016

(HealthDay)—Nine out of 10 Lasik laser eye surgery patients report satisfaction afterwards. But a sizable percentage experience new visual disturbances—like seeing halos around lights—up to six months after the procedure, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.